Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

  • PerkinElmer to Donate 1 Million Rapid COVID-19 Antigen Tests to Combat the Pandemics Second Wave in India

    As India faces a second wave of COVID-19, PerkinElmer Inc., a global leader committed to innovating for a healthier world, will donate 1 million PerkinElmer COVID-19 Antigen Tests to the Government of India to help accelerate testing capabilities across the country. With the support of the US-India Strategic Partnership Forum, PerkinElmer COVID-19 Antigen Test kits will be distributed to government hospitals and testing centers across 10 states of India.

  • Lilly accelerating baricitinibs availability in India

    Eli Lilly and Company announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

  • Alligators mitazalimab shown to enhance cancer vaccine

    Alligator Bioscience announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.

    The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine.

  • Gene therapy in alzheimers disease mouse model preserves learning and memory

    Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimers disease, a key step toward eventually testing the approach in humans with the neurodegenerative disease. The findings are published online in advance of the June 11, 2021 issue of Molecular Therapy-Methods & Clinical Development. 

  • One of the Worlds Largest Healthcare Projects with 5000 NHS-Standard Clinics and 11 Medicities Gets Started

    Indo UK Clinics an integral part of one of the largest healthcare projects in the world encompassing 5000 clinics and 11 medicities pan-India using NHS expertise, equipment and suppliers gets started with first Indo UK Clinic becoming operational in Ludhiana, Punjab. The objective of setting up 5000 diagnostic centers and clinics is a part of inter-governmental discussions between India and the UK at Commonwealth Heads of Government Meeting (CHOGM) level in 2018.

  • Accenture fast-tracks Mankind Pharma digital transformation with data-driven cloud platform

    Accenture is now working with Mankind Pharma, India’s 4th largest pharmaceutical manufacturing company as per as per IQVIA, to speed up its digital transformation to become an intelligent enterprise, improving business agility, performance, and operational efficiency.

  • NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

    Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

  • Glenmark launches Ryaltris AZ at an affordable price in India

    Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris - AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country.

  • Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants

    A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.

  • Personalised medications possible with 3D printing

    Customised medicines could one day be manufactured to patients' individual needs, with University of East Anglia (UEA) researchers investigating technology to 3D 'print' pills.

    The team, including Dr Andy Gleadall and Prof Richard Bibb at Loughborough University, identified a new additive manufacturing method to allow the 3D printing of medicine in highly porous structures, which can be used to regulate the rate of drug release from the medicine to the body when taken orally.

Subscribe to Pharma News